<DOC>
	<DOCNO>NCT02854748</DOCNO>
	<brief_summary>This study randomize , open-label , multiple dosing , crossover study evaluate drug-drugs interaction Lobeglitazone Empagliflozin healthy male volunteer</brief_summary>
	<brief_title>Evaluate Drug-drugs Interaction Between Lobeglitazone Empagliflozin</brief_title>
	<detailed_description>To healthy male subject 30 , follow treatment administer dose 3 period ( Lobeglitazone Empagliflozin Lobe.+Empa . ) wash-out period minimum 7 day . Test Drug 1 : Lobeglitazone 0.5mg 1T Test Drug 2 : Empagliflozin 25mg 1T Pharmacokinetic blood sample collect 24hrs . Safety , pharmacokinetic drug-drugs interaction assess .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>1 . A healthy person whose age 19 45 screening test 2 . Whose weight 55 kg , BMI 18.5 29.9 screening test . ( BMI ( kg/m2 ) = weight ( kg ) / { height ( ) } 2 ) 3 . A male congenital chronic disease three year , history symptom internal treatment , knowledge area 4 . Due special characteristic drug , participators must qualify clinical screening test 5 . The participant must ability willingness participate throughout entire trial 1 . A person history clinically significant cardiovascular , respiratory , liver , kidney , endocrine system , immune system , urinary system disease , bloodtumor disease , mental illness . 2. Who history gastrointestinal related disease affect drug absorption ( esophageal achalasia , esophagostenosis , esophageal disease , Crohn 's disease ) surgery ( except simple appendectomy herniotomy ) 3. Who history hypersensitivity reaction Empagliflozin Lobeglitazone similar series excipient ingredient ( aspirin , fibrate , antibiotic , etc . ) 4 . A person whose electrocardiogram value include QTc &gt; 450 msec , PR interval &gt; 200 msec , QRS duration &gt; 120 msec screening , show clinically significant opinion . 5. Who fall follow result 1 . Liver Function Test ( AST , ALT ) exceed 1.5x upper limit normal range 2. eGFR &lt; 60mL/min/1.73m2 6. Who show vital sign value 150 mmHg less 90 mmHg systolic pressure 95 mmHg less 60 mmHg diastolic blood pressure 7. Who history drug abuse show positive result urinary drug screen 8. Who take prescribe drug , medicinal plant within 2 week first day dose take overthecounter drug vitamin supplement within 1 week ( , condition meet , still participate clinical test researcher 's judgment ) 9. Who take investigational drug bioequivalence drug within 3 month first day dose 10. Who participate whole blood donation within 2 month first dose , platelet donation within 1 month . Who receive blood month first day dose 11. Who constantly drink alcohol ( 21 units/week , 1 unit = 10 g pure alcohol ) stop drinking alcohol clinical test . 12. Who smoke 10 cigarette per day within 3 month , quit smoking hospitalize 13. Who limit intake grapefruit grapefruit contain food 48hrs first dose clinical test drug collect pharmacokinetic blood sample 14. Who absorb caffeinated drink ( coffee , tea ( black green tea ) , soda , coffee flavor milk , energy drink , etc . ) stop absorb 24 hour hospitalization discharge 15 . Not use reliable contraception , plan pregnancy study 16. Who Galactose intolerance , LAPP lactose intolerance , glucosegalactose malabsorption genetic disorder 17 . Person determine unsuitable participate test researcher</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>